Last modified: August 25, 2010
- Aileron Therapeutics
Companies[edit]
Web Presences[edit]
Financial Profiles[edit]
- Biotech & Life Sciences
Industries[edit]
Recent Updates |
|---|
| Diane Jorkasky has been been added to Aileron Therapeutics. |
| Diane Jorkasky has been featured in Event Coverage – Women Leaders in Life Sciences. |
| Diane Jorkasky is attending Women Leaders in Life Sciences. |
| Diane Jorkasky has been featured in Women Leaders in Life Sciences event - October 6. |
| Diane Jorkasky has been added to the Ecosystem. |
Description[edit]
Dr. Diane Jorkasky is a 23 year veteran of the pharmaceutical industry with experience in Phase 1 through Phase 4. She is currently SVP, head of Development and Chief Medical Officer at Aileron Therapeutics in Cambridge, Massachusetts, where she is involved in the development of stapled peptides. Prior to this appointment she had been Vice President of Global Clinical Research Operations, its clinical research units and leader of the Operational Excellence Board for Development at the Pfizer Global Research and Development New London, Connecticut. In this role, Dr. Jorkasky was responsible for ensuring that all exploratory development, clinical pharmacology (phase 1-4), translational medicine and clinical technology studies were conducted and reported. She led the complete alignment of the three Pfizer Clinical Research Units, located in the US, Europe and Asia, such that they operated as one clinical unit and were recently awarded certification by American Accreditation for Human Rights Protection Policies for their clinical research process, the first in industry to achieve such a recognition. In her role as leader of the Operation Excellence Board for Development, she drove data standards and improvements in Pfizer’s drug development process to gain efficiencies in timelines and performance from Phase 1 to 4. Dr. Jorkasky also established the Pfizer alliance in PET imaging with Yale Medical School, which, after its 7th year, had produced 66 peer reviewed publications and 10 critical decision studies for Pfizer. She is particularly interested in ensuring scientific strategy is realized through innovative application of technology to the operations. Dr Jorkasky is a member of the Connecticut Academy of Science and Technology. She has been recognized by the Connecticut Women’s Hall of Fame for her scientific leadership and mentoring of young women and the Connecticut Council on Technology for her work in driving the technological improvements in the clinical research units. Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology. She is on the faculties of Yale, Penn and Uniformed Service of Health Sciences Medical Schools. She has published on over 100 peer review articles. Most recently Dr. Jorkasky was selected to be a Woodrow Wilson visiting fellow.





